Biote subsidiary recalls hormone pellets due to metal particulate; expects $1.3M Q4 charge

biote Corp.

Asteria Health voluntarily recalled specific lots of hormone pellets shipped May 20, 2025–Jan 19, 2026 due to potential metal particulate.
Expects ~$1.3M one-time charge in Q4 2025 cost of products for write-off of impacted inventory.
Additional recall costs in 2026 estimated at ~$1.0M; recall conducted with FDA knowledge.
Company states recall does not materially impact ability to supply practitioners or service patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.